SCHOTT Pharma Reports a Strong Beginning to 2026

SCHOTT Pharma has commenced its 2026 financial year with a positive performance, posting a 4.8% revenue increase at constant currencies, reaching EUR 240.2 million. The reported growth stands at 3.8%. The EBITDA surged by 11.1%, amounting to EUR 65.2 million, pushing the EBITDA margin to 27.1%, compared to 25.4% in Q1 2025.

The Drug Containment Solutions segment was pivotal, with a revenue of EUR 137.2 million, an impressive 9.4% rise at constant currencies. This growth was fueled by the demand for sterile cartridges and specialty vials, achieving an EBITDA margin of 24.3%.

Meanwhile, the Drug Delivery Systems segment maintained its previous year's level with revenues of EUR 103.1 million. However, EBITDA declined by 7.3%, largely due to lower polymer syringe production utilization and new capacity ramp-up costs in Hungary.

SCHOTT Pharma confirms its 2026 outlook, anticipating 2–5% revenue growth and an EBITDA margin of about 27%.